Immunotherapy eradicates metastases with reversible defects in MHC class i expression

Cancer Immunology, Immunotherapy

Volumn 60, Issue 9, 2011, Pages 1257-1268

  Garrido, Cristina ^a,b   Romero, Irene ^b   Berruguilla, Enrique ^b   Cancela, Bárbara ^b   Algarra, Ignacio ^c   Collado, Antonia ^b   García Lora, Angel ^b   Garrido, Federico ^a,b  

^a UNIVERSITY OF GRANADA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c UNIVERSITY OF JAÉN   (Spain)

Author keywords

Immunotherapy; Metastases; MHC class I; Reversible defects

Indexed keywords

ANTIGEN PROCESSING MACHINERY PROTEIN; APM PROTEIN; BETA 2 MICROGLOBULIN; CALNEXIN; CALRETICULIN; CPG OLIGODEOXYNUCLEOTIDE; CPG OLIGODEOXYNUCLEOTIDE 1826; DOCETAXEL; GAMMA INTERFERON; GENE PRODUCT; H 2 CLASS I HEAVY CHAIN; KRESTIN; LMP2 PROTEIN; LMP7 PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN BOUND POLYSACCHARIDE K; TAP2 PROTEIN; TAPASIN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PROCESSING MACHINERY GENE; APM GENE; ARTICLE; AUTOLOGOUS IRRADIATED GR9 A7 CELL; BETA2 MICROGLOBULIN GENE; CALNEXIN GENE; CALRETICULIN GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CD3+ CD4+ CD25+ FOXP3+ T LYMPHOCYTE; CD3+ CD4+ T LYMPHOCYTE; CD3+ CD49+ T LYMPHOCYTE; CD3+ CD8+ T LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD3- CD19+ T LYMPHOCYTE; CD3- CD49+ T LYMPHOCYTE; CD4+ CD25+ FOXP3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; CONTROLLED STUDY; DOWN REGULATION; FIBROSARCOMA; FLOW CYTOMETRY; GENE; GENE EXPRESSION; H 2 CLASS 1 HEAVY CHAIN GENE; LMP2 GENE; LMP7 GENE; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTE SUBPOPULATION; MALE; METASTASIS; METASTASIS INHIBITION; MONOTHERAPY; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TAP1 GENE; TAP2 GENE; TAPASIN GENE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FIBROSARCOMA; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MICE; MICE, INBRED BALB C; PROTEOGLYCANS; TAXOIDS;

EID: 80054710985     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1027-1     Document Type: Article

References (49)

1. Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411:380-384 (Pubitemid 32467048)
2. Schadendorf D, Algarra SM, Bastholt L, Cinat G, Dreno B, Eggermont AM, Espinosa E, Guo J, Hauschild A, Petrella T et al (2009) Immunotherapy of distant metastatic disease. Ann Oncol 20(Suppl 6):vi41-vi50
3. Godelaine D, Carrasco J, Lucas S, Karanikas V, Schuler-Thurner B, Coulie PG, Schuler G, Boon T, Van Pel A (2003) Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J Immunol 171:4893-4897 (Pubitemid 37310612)
4. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P (2006) Human T cell responses against melanoma. Annu Rev Immunol 24:175-208
5. Anichini A, Vegetti C, Mortarini R (2004) The paradox of T cellmediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol Immunother 53:855-864 (Pubitemid 39312653)
6. de la Cruz-Merino L, Grande-Pulido E, Albero-Tamarit A, Codes- Manuel de Villena ME (2008) Cancer and immune response: old and new evidence for future challenges. Oncologist 13:1246-1254
7. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909-915 (Pubitemid 39273730)
8. Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, Royal RE, Kammula U, Restifo NP, Hughes MS et al (2005) Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 175:6169-6176 (Pubitemid 41508105)
9. Ahmad M, Rees RC, Ali SA (2004) Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 53:844-854 (Pubitemid 39312652)
10. Smyth MJ, Dunn GP, Schreiber RD (2006) Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90:1-50 (Pubitemid 43765795)
11. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18:89-95 (Pubitemid 27107103)
12. Seliger B, Cabrera T, Garrido F, Ferrone S (2002) HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 12:3-13 (Pubitemid 34087893)
13. Chang CC, Campoli M, Restifo NP, Wang X, Ferrone S (2005) Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. J Immunol 174:1462-1471
14. Cabrera T, Lara E, Romero JM, Maleno I, Real LM, Ruiz-Cabello F, Valero P, Camacho FM, Garrido F (2007) HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Immunol Immunother 56:709-717 (Pubitemid 46348739)
15. Carretero R, Romero JM, Ruiz-Cabello F, Maleno I, Rodriguez F, Camacho FM, Real LM, Garrido F, Cabrera T (2008) Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics 60:439-447
16. Aptsiauri N, Carretero R, Garcia-Lora A, Real LM, Cabrera T, Garrido F (2008) Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunol Immunother 57:1727-1733
17. Garrido F, Cabrera T, Aptsiauri N (2010) Hard and soft lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 127:249-256
18. Fisher M, Yang LX (2002) Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. Anticancer Res 22:1737-1754 (Pubitemid 34839190)
19. Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J (1994) Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study group of Immunochemotherapy with PSK for Gastric Cancer. Lancet 343:1122-1126 (Pubitemid 24142032)
20. Munemoto Y, Iida Y, Ohata K, Saito H, Fujisawa K, Kasahara Y, Mitsui T, Asada Y, Miura S (2004) Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: identification of responders incorporating the age factor. Oncol Rep 11:623-635
21. Ohwada S, Ikeya T, Yokomori T, Kusaba T, Roppongi T, Takahashi T, Nakamura S, Kakinuma S, Iwazaki S, Ishikawa H et al (2004) Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomized controlled study. Br J Cancer 90:1003-1010 (Pubitemid 38495819)
22. Katoh R, Ooshiro M (2007) Enhancement of antitumor effect of tegafur/uracil (UFT) plus leucovorin by combined treatment with protein-bound polysaccharide, PSK, in mouse models. Cell Mol Immunol 4:295-299
23. Sakamoto J, Morita S, Oba K, Matsui T, Kobayashi M, Nakazato H, Ohashi Y (2006) Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother 55:404-411 (Pubitemid 43076892)
24. Ueda Y, Fujimura T, Kinami S, Hirono Y, Yamaguchi A, Naitoh H, Tani T, Kaji M, Yamagishi H, Miwa K (2006) A randomized phase III trial of postoperative adjuvant therapy with S-1 alone versus S-1 plus PSK for stage II/IIIA gastric cancer: Hokuriku- Kinki immunochemo-therapy study group-gastric cancer. Jpn J Clin Oncol 36:519-522 (Pubitemid 44592681)
25. Garrido A, Perez M, Delgado C, Garrido ML, Rojano J, Algarra I, Garrido F (1986) Influence of class I H-2 gene expression on local tumor growth. Description of a model obtained from clones derived from a solid BALB/c tumor. Exp Clin Immunogenet 3:98-110
26. Perez M, Algarra I, Ljunggren HG, Caballero A, Mialdea MJ, Gaforio JJ, Klein G, Karre K, Garrido F (1990) A weakly tumorigenic phenotype with high MHC class-I expression is associated with high metastatic potential after surgical removal of the primary murine fibrosarcoma. Int J Cancer 46:258-261 (Pubitemid 20252086)
27. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J et al (2006) Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203:1259-1271 (Pubitemid 43736595)
28. Jimenez-Medina E, Berruguilla E, Romero I, Algarra I, Collado A, Garrido F, Garcia-Lora A (2008) The immunomodulator PSK induces in vitro cytotoxic activity in tumour cell lines via arrest of cell cycle and induction of apoptosis. BMC Cancer 8:78
29. Ellis LM, Fidler IJ (2010) Finding the tumor copycat. Therapy fails, patients don't. Nat Med 16:974-975
30. Benitez R, Godelaine D, Lopez-Nevot MA, Brasseur F, Jimenez P, Marchand M, Oliva MR, van Baren N, Cabrera T, Andry G et al (1998) Mutations of the β2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of 2 patients immunized with MAGE peptides. Tiss Antigens 52:520-529 (Pubitemid 29002755)
31. Riker A, Cormier J, Panelli M, Kammula U, Wang E, Abati A, Fetsch P, Lee KH, Steinberg S, Rosenberg S et al (1999) Immune selection after antigen-specific immunotherapy of melanoma. Surgery 126:112-120 (Pubitemid 29382769)
32. Hoffmann TK, Nakano K, Elder EM, Dworacki G, Finkelstein SD, Appella E, Whiteside TL, DeLeo AB (2000) Generation of T cells specific for the wild-type sequence p53 (264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants. J Immunol 165:5938-5944
33. Carretero R, Cabrera T, Gil H, Saenz-Lopez P, Maleno I, Aptsiauri N, Cozar JM, Garrido F (2010) BCG immunotherapy of bladder cancer induces selection of HLA class I-deficient tumor cells. Int J Cancer [Epub ahead of print]
34. Jimenez E, Garcia-Lora A, Martinez M, Garrido F (2005) Identification of the protein components of protein-bound polysaccharide that interact with NKL cells. Cancer Immunol Immunother 54:395-399 (Pubitemid 40246339)
35. Okuzawa M, Shinohara H, Kobayashi T, Iwamoto M, Toyoda M, Tanigawa N (2002) PSK: a protein-bound polysaccharide, overcomes defective maturation of dendritic cells exposed to tumorderived factors in vitro. Int J Oncol 20:1189-1195
36. Asai H, Iijima H, Matsunaga K, Oguchi Y, Katsuno H, Maeda K (2008) Protein-bound polysaccharide K augments IL-2 production from murine mesenteric lymph node CD4+ T cells by modulating T cell receptor signaling. Cancer Immunol Immunother 57:1647-1655
37. Algarra I, Ohlen C, Perez M, Ljunggren HG, Klein G, Garrido F, Karre K (1989) NK sensitivity and lung clearance of MHC-class- I-deficient cells within a heterogeneous fibrosarcoma. Int J Cancer 44:675-680 (Pubitemid 19258743)
38. Whitmore MM, DeVeer MJ, Edling A, Oates RK, Simons B, Lindner D, Williams BR (2004) Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res 64:5850-5860 (Pubitemid 39095586)
39. Kawai T, Akira S (2006) Innate immune recognition of viral infection. Nat Immunol 7:131-137 (Pubitemid 43135878)
40. Ohwada S, Ogawa T, Makita F, Tanahashi Y, Ohya T, Tomizawa N, Satoh Y, Kobayashi I, Izumi M, Takeyoshi I et al (2006) Beneficial effects of protein-bound polysaccharide K+ tegafur/uracil in patients with stage II or III colorectal cancer: analysis of immunological parameters. Oncol Rep 15:861-868
41. Oba K, Teramukai S, Kobayashi M, Matsui T, Kodera Y, Sakamoto J (2007) Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol Immunother 56:905-911 (Pubitemid 46729147)
42. Garnett CT, Schlom J, Hodge JW (2008) Combination of docetaxel and recombinant vaccine enhances T cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res 14:3536-3544
43. Kohlmeyer J, Cron M, Landsberg J, Bald T, Renn M, Mikus S, Bondong S, Wikasari D, Gaffal E, Hartmann G et al (2009) Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy. Cancer Res 69:6265-6274
44. Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, Beetham P, Tsang KY, Grosenbach DW, Feldman J et al (2006) A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 12:1260-1269 (Pubitemid 43342517)
45. Nistico P, Capone I, Palermo B, Del Bello D, Ferraresi V, Moschella F, Arico E, Valentini M, Bracci L, Cognetti F et al (2009) Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int J Cancer 124:130-139
46. Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, Cho HI, Antonia S, Altiok S, Celis E, Gabrilovich DI (2010) Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 120:1111-1124
47. Garcia-Lora A, Algarra I, Gaforio JJ, Ruiz-Cabello F, Garrido F (2001) Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants. Int J Cancer 91:109-119
48. Garcia-Lora A, Martinez M, Algarra I, Gaforio JJ, Garrido F (2003) MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int J Cancer 106:521-527 (Pubitemid 36966208)
49. Garrido F, Algarra I, Garcia-Lora AM (2010) The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible hard lesions. Cancer Immunol Immunother 59:1601-1606